Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating

Spyre Therapeutics, Inc. (NASDAQ:SYRE) is among the 14 champion booming stocks to bargain close now. On January 5, Wells Fargo reiterated a Buy standing connected the stock, with a terms people of $40.

The update follows Mizuho’s initiation of sum connected the banal connected December 18 with an Outperform standing and a stock terms people of $53, wherever it cited imaginable successful the company’s pipeline of anti-monoclonal antibodies to dainty inflammatory bowel illness (IBD).

In November, the biotech institution shared affirmative findings from its Phase 1 quality proceedings of SPY003, an extended half-life antibody to cure IBD. The tests performed connected 59 participants with varying doses showed that the cause was good received astatine each levels, with a half-life of astir 85 days, strengthening the lawsuit for quarterly oregon 2 yearly attraction doses.

According to TipRanks, successful a probe enactment to investors, Mizuho praised the company’s expertise successful investigating caller combinations for treatments, which could assistance thrust maturation successful the future. The steadfast projects Spyre Therapeutics, Inc. (NASDAQ:SYRE)’s planetary income to scope $1.7 cardinal by 2035.

Wall Street analysts person a bullish outlook connected the banal with a statement Strong Buy standing and a one-year mean stock terms people of $56.67, representing an upside of 72.77% arsenic of January 12.

The company’s shares person surged by implicit 69% successful the past 3 months, driven by increasing investors’ optimism from proceedings results for SPY003, promising caller expert updates, and third-quarter results successful November, which showed a crisp diminution successful nett nonaccomplishment from $69 cardinal successful the anterior year’s play to $11.2 million.

Spyre Therapeutics, Inc. (NASDAQ:SYRE) is simply a biotechnology institution focused connected processing treatments for inflammatory bowel and rheumatic diseases.

While we admit the imaginable of SYRE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.